Recent Posts

Categorizing members really isn't so black or white. People don't like to be categorized (we all value our uniqueness) but that seems to be the way of the world these days. I tend to look at the content/quality of each post.

The ones I appreciate most are informational. Whether positive or negative, they present some rationale for readers to consider and nearly always include a link where readers can go to get more information. I consider screenshots of real world patients posted by sportsrancho , harryx1 and others to be informational. The same with peppy posting numbers related to daily stock activity, sla55 for keeping us updated on NASDAQ short interest and many others who go out of their way to research the medical/stock market responses to MannKind/Afrezza.

As a moderator, it's not easy to identify any member's intent.  For example, is a post that lambasts management coming from an investor whose stock value is 1/10th of what is was when s/he invested or is it someone who loves pouring salt into a wound and prodding those who are hurting?

Obviously, opinions matter. Some members have experience with the pharmaceutical industry, stock trading, finance, etc. and are willing to share it. Other opinions are speculative.  My oft-quoted mantra that "the science will prevail" is somewhere in the middle. My reality, as an investor, is that the pharmaceutical industry is much more cut-throat than I ever imagined and roadblocks have emerged where I least expected. This past 5 years has been highly educational for me thanks to many ProBoard members, some of whom have moved on.

I imagine that many of you think I should remove certain posts that you find personally offensive and perhaps we staff could do a better job of reining in hostility when it erupts.  But all members of this staff are volunteers and most of us work full-time jobs.

I guess what I'm saying is that, even though emotions have risen over the past year leading to a more vitriolic atmosphere here at ProBoards-MNKD, this forum remains the premier place to enhance your understanding of this company and its products*, the medical and regulatory industry and the stock market with all its goods and evils.

*Better sources of specific product information are found at sites like:

Afrezza.com www.afrezza.com/ and;

Afrezza:Just Breathe www.afrezzajustbreathe.com/

joey - While your comments about CEO Mike Castagna's circles is spot on, MannKind's new CFO Steve Binder is no slouch, either, moving back to the USA from Singapore, where he was CFO of Stryker Corporation (a medical device company with a 2Q18 net revenue of $3.3 billion) and, prior to that, VP Finance at Bristol-Myers Squibb Company.